Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.43 |
| ▸ | CTSS | P25774 | 7/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26269789 | 0.86 | CTSK (0.43) | CTSKCTSSJAK3BTKCA1 | |
| SCHEMBL24924763 | 0.86 | CTSK (0.43) | CTSKCTSSJAK3BTKCA1 | |
| SCHEMBL18290341 | 0.83 | MEN1 (0.49) | CTSKCTSSJAK3BTKCA1 | |
| SCHEMBL13413129 | 0.82 | CTSK (0.55) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL18354057 | 0.82 | GAA (0.44) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL5438237 | 0.82 | CTSK (0.55) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL30918332 | 0.82 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL14842208 | 0.81 | CTSK (0.43) | CTSKCTSSJAK3BTKCA1 | |
| SCHEMBL14496975 | 0.81 | CTSK (0.43) | CTSKCTSSJAK3BTKCA1 | |
| SCHEMBL14779393 | 0.79 | CTSK (0.57) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331750-A1 | Preparation Method for Glufosinate | LIER CHEMICAL CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331750-A1 | Preparation Method for Glufosinate | LIER CHEMICAL CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331750-A1 | Preparation Method for Glufosinate | GLUL, ASNS, GDA | CTSK 2841/4885CTSS 1590/4885JAK3 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.